Lucence raises $20 million Series A for its non-invasive cancer screening technology

TechCrunch | 11/19/2019 | Staff
Click For Photo: https://techcrunch.com/wp-content/uploads/2019/11/Dr-Min-Han-Tan.jpg?w=600

Lucence Diagnostics, a genomic medicine startup that develops non-invasive tests for cancer screening, announced today that it has raised a $20 million Series A led by IHH Healthcare, one of the world’s largest integrated private healthcare groups. Other participants included SGInnovate and returning investors Heliconia Capital (a subsidiary of Temasek Holdings), Lim Kaling and Koh Boon Hwee.

The round will be used for scaling Lucence’s labs, hiring and making its products commercially available to more patients in Asia and North America.

Funding - Trials - Technology - Sensitivity - Variables

The funding will also support two prospective clinical trials. One will focus on its technology’s sensitivity to actionable variables in late-stage cancer patients, while the other will evaluate its use for early-stage detection in several types of cancer, including lung, colorectal, breast and pancreatic. Lucence is currently designing a study that will involve 100,000 participants to validate its early-stage detection test. It will recruit its first patient in the middle of next year and launch in the United States and Asia.

Together with its seed funding, this round brings Lucence’s total raised so far to $29.2 million.

Lucence - Tests - Physicians - Southeast - Asia

Lucence’s tests are currently used by physicians in Southeast Asia and Hong Kong, and it plans to expand further in North America and East Asia. Its lab in Singapore has received both CLIA certification and CAP accreditation, which means its tests can be used by doctors and patients in...
(Excerpt) Read more at: TechCrunch
Wake Up To Breaking News!
Nie wieder, unelected bureaucrat's running our country
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!